Ovarian Cancer Clinical Trials 2024

What are the top hospitals conducting ovarian cancer research?

When it comes to cutting-edge clinical trials in the battle against ovarian cancer, several top hospitals are making significant strides. In Houston, M D Anderson Cancer Center stands out with 11 ongoing trials dedicated to ovarian cancer and an impressive record of 49 completed studies since their first trial in 2003. Massachusetts General Hospital in Boston is also at the forefront, currently conducting 10 active ovarian cancer trials and having amassed a total of 56 trials over time since they began investigating this disease back in 2002.

Meanwhile, Memorial Sloan Kettering Cancer Center in New york has made substantial contributions as well. They have six ongoing ovarian cancer trials and have conducted a noteworthy total of 60 trials since recording their inaugural study in 1994. On the West Coast, Kaiser Permanente Los Angeles Medical Center takes part with six active ovarian cancer trials while they've accumulated eleven previous investigations; their commitment started relatively recently with their first recorded trial taking place just sixteen years agoin2005.

Additionally adding itself to this list is Mayo Clinic located at Arizona's Scottsdale where there are aroundsixongoing clinical tests concerningovarian carcinoma while fifteencompleted experiments priorly wereconducted by them within thatfieldw

Which are the best cities for ovarian cancer clinical trials?

Los Angeles, California; New york, New York; and Boston, Massachusetts are notable cities for ovarian cancer clinical trials. Los Angeles has 37 active trials investigating treatments like Paclitaxel, Bevacizumab, and Cisplatin. In New York City, there are 36 ongoing studies focused on BMS-986340, Paclitaxel, LY3537982 among others. Meanwhile in Boston researchers are conducting 36 active trials exploring Olaparib 300mg tablets, Dendritic Cell/Tumor Fusion Vaccine and Bevacizumab as potential treatment options. These cities offer individuals with ovarian cancer access to cutting-edge clinical trials and potential breakthroughs in care.

Which are the top treatments for ovarian cancer being explored in clinical trials?

Clinical trials are at the forefront of advancing treatments for ovarian cancer, with several promising options currently under exploration. Paclitaxel, a well-established drug since 1999, is being tested in five active trials and has participated in an impressive 155 all-time ovarian cancer trials. Another contender making waves is niraparib, introduced in 2015 and currently involved in five ongoing trials along with a track record of 45 all-time studies for ovarian cancer. Additionally, bevacizumab shows promise with its involvement in five active clinical trials and participation in 80 all-time ovarian cancer trials since its introduction back in 2003. Lastly, carboplatin remains relevant after two decades since first listed; it is currently participating in three active clinical trials while having been included across an extensive history of 141 all-time ovarian cancer studies. These innovative developments hold great potential to improve outcomes for individuals battling this complex disease.

What are the most recent clinical trials for ovarian cancer?

Exciting advancements in ovarian cancer research offer hope for improved treatment options. Recent clinical trials have explored various approaches to tackle this disease. One such trial, Part II Multiple Participant Cohort RO7515629 Dose Escalation, combines Phase 1 and Phase 2 studies to investigate the effectiveness of a new therapy for ovarian cancer patients. Another study focuses on AB-1015, a potential treatment that has entered Phase 1 testing with encouraging results so far. Additionally, SGN-PDL1V is being evaluated in a Phase 1 trial as a targeted therapy specifically designed for ovarian cancer patients. Paclitaxel is also under investigation in a Phase 2 study aiming to gain further insights into its efficacy against ovarian cancer. With these ongoing trials and their promising findings, there is renewed optimism surrounding the future of ovarian cancer treatments.

What ovarian cancer clinical trials were recently completed?

Several clinical trials for ovarian cancer have recently reached completion, demonstrating progress in the pursuit of improved treatments. Among them is a trial sponsored by Astellas Pharma Global Development, Inc., investigating ASP0739, which concluded in January 2022. Additionally, the Masonic Cancer Center at the University of Minnesota completed a trial evaluating Enoblituzumab in April 2021. Furthermore, Rucaparib was studied in a trial sponsored by pharmaand GmbH and finished its course in March 2021. These recent advancements signify the ongoing efforts to combat ovarian cancer and provide hope for patients facing this challenging disease.